Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information MR PHILIP POWELL BComm (Hons) ACA MAICD Non-Executive Director (appointed 17 June 2019) Mr Powell is a Chartered Accountant with extensive experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles. Mr Powell is a former Non-Executive Director of RMA Global Ltd (ASX: RMY), PolyNovo Ltd (ASX: PNV) and Medical Developments International Ltd (ASX: MVP). Mr Powell is the Chair of the Company’s Audit & Risk Committee. Mr Powell has not been a director of any listed companies in the last three years other than those listed above. MS MARY HARNEY IDP-C INSEAD, BSc, BA (Fine Arts), MAICD FIML Non-Executive Director (appointed 1 October 2024) Ms Harney is an experienced Non-Executive Director and Chief Executive and brings a deep understanding of applied life science research, in addition to experience in biopharmaceutical regulatory affairs and commercialisation. Ms Harney is the Director of specialist consulting firm Mary Harney Advisory providing leadership, governance and strategic advice across innovation industries such as health, biotech and agriculture. Ms Harney currently serves as Chair of private Australian biotech Oncology One Pty Ltd, a cancer drug discovery company. Ms Harney was also previously the Chair of Race Oncology (ASX: RAC), and a former Chair of Microbio Limited. Ms Harney has not been a director of any listed companies in the last three years other than those listed above. INTERESTS IN THE SHARES AND OPTIONS OF THE COMPANY AND RELATED BODIES CORPORATE As at the date of issuing this report, the interests of the current directors in the shares of the Company were: Ordinary Shares ESS Options Listed Options Mr David Williams 5,179,337 6,450,000 90,000 Dr Geoffrey Cumming 237,414 250,000 30,000 Mr Max Johnston 804,310 250,000 100,000 Mr Philip Powell 584,630 250,000 30,000 Ms Mary Harney – 250,000 – EXECUTIVE MANAGEMENT AND COMPANY SECRETARY CHIEF EXECUTIVE OFFICER DR LEEARNE HINCH BSc BVMS MBA (appointed 7 November 2016) Dr Hinch is a seasoned biotechnology CEO and entrepreneur with a proven track record in corporate strategy, business management, capital raising, investor relations, M&A, business development and partnering. Leearne has successfully led INOVIQ’s transformation from a single-asset diagnostics company to a diversified biotech, through M&A, advancing its cancer diagnostics and therapeutics pipeline, securing a global commercial partner for its proprietary exosome isolation tools and building an experienced team. She previously established life sciences consulting firm Ingeneus Solutions Pty Ltd and has held past leadership roles as a biotechnology executive and consultant at Eustralis Pharmaceuticals Ltd, HealthLinx Ltd (ASX: HTX), OBJ Ltd (ASX: OBJ), Holista Colltech Ltd (ASX: HCT) and Chemeq Ltd (ASX: CMQ), where she gained extensive experience leading strategic, development and commercial programs across diagnostics, medical devices and therapeutics. She also worked for multinationals Virbac and Mars Petcare. Dr Hinch holds Bachelor of Science, Bachelor of Veterinary Medicine and Surgery and Master of Business Administration qualifications. 17 Annual Report 2025
RkJQdWJsaXNoZXIy MjE2NDg3